Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.
Find out more at https://www.novartis.com
Yehudit Gabriel
yehudit.gabriel@novartis.com
054-5211248
לקוסנטיקס נוספה אינדיקציה נוספת המאושרת במשרד הבריאות בישראל 2:
Non-radiographic axial spondyloarthritis (nr-axSpA)
הוספת מינון ה300 מ"ג לטיפול בקוסנטיקס באינדיקציית (AS) Ankylosing Spondylitis 2:
The recommended dose is 150 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg. Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Cosentyx indications as approved in Israel 2:
Plaque psoriasis:
Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Psoriatic arthritis:
Secukinumab, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Axial spondyloarthritis (axSpA):
Ankylosing spondylitis (AS, radiographic axial spondyloarthritis):
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Non-radiographic axial spondyloarthritis (nr-axSpA):
Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs).
Cosentyx is backed by more than 12 years of clinical experience with more than 400,000 patients treated worldwide with Cosentyx since launch 1.
References:
-
Novartis press release. Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis. Feb 26,2021
-
Cosentyx API approved by the MoH Apr 2021
לעלון לרופא של Cosentyx מתוך אתר משרד הבריאות:
https://data.health.gov.il/drugs/alonim/Rishum_18_71979421.pdf